Nautilus Biotechnology, Inc. (NAUT) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, Nautilus Biotechnology, Inc. (NAUT) trades at a price-to-earnings ratio of -5.6x, with a stock price of $2.62 and trailing twelve-month earnings per share of $-0.50.
Compared to the Healthcare sector median P/E of 23.2x, NAUT trades at a 124% discount to its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, NAUT trades at a notable discount to the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NAUT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Diagnostics and Omics Tools peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 44.2Lowest | -Best | +165%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See NAUT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAUT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NAUT vs LLY
See how NAUT stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is NAUT stock overvalued or undervalued?
NAUT current P/E: -5.6x. 5-year average P/E: N/A. Percentile: N/A.
How does NAUT's valuation compare to peers?
Nautilus Biotechnology, Inc. P/E of -5.6x compares to sector median of 23.2x. The discount suggests lower growth expectations or higher risk.
What is NAUT's PEG ratio?
NAUT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.